# Nuclide record iobenguane-i-131 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/iobenguane-i-131/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "iobenguane-i-131" ;
  schema:name "Iobenguane I-131 (therapeutic)"@en ;
  schema:alternateName "131I-MIBG"@en, "Ultratrace iobenguane"@en, "Azedra" ;
  schema:description "Azedra was a radioactive drug that homed in on adrenal-type tumours (phaeochromocytoma and paraganglioma) that could not be removed and delivered radiation from inside. It was approved in 2018 and discontinued by its maker in 2024."@en ;
  schema:url <https://nuclide.cc/drugs/iobenguane-i-131/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Iobenguane> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=iobenguane>, <https://www.cancer.gov/about-cancer/treatment/drugs/iobenguanei131> ;
  nuclide:status "withdrawn" ;
  nuclide:tag "nci-list" ;
  nuclide:modality "Radiopharmaceutical therapy (beta and gamma emitter)" ;
  nuclide:approval "US 2018: Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (discontinued 2024)" ;
  nuclide:related <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/i-131/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/mibg-theranostics/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:companies <https://nuclide.cc/companies/lantheus/> ;
  nuclide:terms <https://nuclide.cc/terms/radioiodine-term/> .